Impact of Vutrisiran on Quality of Life and Physical Function in Patients with Hereditary Transthyretin-Mediated Amyloidosis with Polyneuropathy.

MLA

Obici, Laura, et al. “Impact of Vutrisiran on Quality of Life and Physical Function in Patients with Hereditary Transthyretin-Mediated Amyloidosis with Polyneuropathy.” Neurology & Therapy, vol. 12, no. 5, Oct. 2023, pp. 1759–75. EBSCOhost, https://doi.org/10.1007/s40120-023-00522-4.

APA

Obici, L., Ajroud-Driss, S., Lin, K.-P., Berk, J. L., Gillmore, J. D., Kale, P., Koike, H., Danese, D., Aldinc, E., Chen, C., Vest, J., Adams, D., the HELIOS-A Collaborators Study Group, Wixner, J., Backlund, R., Pilebro, B., Anan, I., Edbom, F., Ekman, A., & Arvidsson, S. (2023). Impact of Vutrisiran on Quality of Life and Physical Function in Patients with Hereditary Transthyretin-Mediated Amyloidosis with Polyneuropathy. Neurology & Therapy, 12(5), 1759–1775. https://doi.org/10.1007/s40120-023-00522-4

Chicago

Obici, Laura, Senda Ajroud-Driss, Kon-Ping Lin, John L. Berk, Julian D. Gillmore, Parag Kale, Haruki Koike, et al. 2023. “Impact of Vutrisiran on Quality of Life and Physical Function in Patients with Hereditary Transthyretin-Mediated Amyloidosis with Polyneuropathy.” Neurology & Therapy 12 (5): 1759–75. doi:10.1007/s40120-023-00522-4.